These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial. Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G Eur Urol Oncol; 2024 Dec; 7(6):1441-1450. PubMed ID: 38664137 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic radiotherapy to oligoprogressive lesions detected with Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965 [TBL] [Abstract][Full Text] [Related]
8. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693 [TBL] [Abstract][Full Text] [Related]
9. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168 [TBL] [Abstract][Full Text] [Related]
10. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242 [TBL] [Abstract][Full Text] [Related]
12. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904 [TBL] [Abstract][Full Text] [Related]
13. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474 [TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide. La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013 [TBL] [Abstract][Full Text] [Related]
15. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
17. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. Massaro M; Facondo G; Vullo G; Aschelter AM; Rossi A; De Sanctis V; Marchetti P; Osti MF; Valeriani M Front Oncol; 2021; 11():695136. PubMed ID: 34631527 [TBL] [Abstract][Full Text] [Related]
18. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection. Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933 [TBL] [Abstract][Full Text] [Related]
19. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119 [TBL] [Abstract][Full Text] [Related]
20. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice. Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC Front Oncol; 2022; 12():862995. PubMed ID: 35656509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]